Suppr超能文献

人肝癌细胞系HepG2中组织型纤溶酶原激活剂与细胞外基质相关的1型纤溶酶原激活剂抑制剂之间的相互作用。

Interactions between tissue-type plasminogen activator and extracellular matrix-associated plasminogen activator inhibitor type 1 in the human hepatoma cell line HepG2.

作者信息

Owensby D A, Morton P A, Schwartz A L

机构信息

Department of Medicine, Washington University School of Medicine, St. Louis, Missouri 63110.

出版信息

J Biol Chem. 1989 Oct 25;264(30):18180-7.

PMID:2553701
Abstract

Hepatic parenchymal cells contribute to the clearance of circulating tissue-type plasminogen activator (t-PA) in vivo. The hepatocyte extracellular matrix is interposed between the endothelial-lined sinusoids and the parenchymal cell surface and thus may influence t-PA clearance. To test this hypothesis, the well differentiated human hepatoma cell line HepG2 was used to characterize the role of extracellular matrix in t-PA clearance in vitro. Previous studies with these cells demonstrated their capacity for specific catabolism of t-PA in a system modulated by plasminogen activator inhibitor type 1 (PAI-1). In the present study the extracellular matrix growth substratum of HepG2 cells is shown to contain active PAI-1. PAI-1 is distributed in a punctuate pattern throughout the substratum. Components of the substratum confer stability to active PAI-1 for intervals of at least 24 h. Exposing substratum to 125I-t-PA leads rapidly to the formation and release of a sodium dodecyl sulfate-stable 95-kDa 125I-t-PA.PAI-1 complex. In comparison, cell monolayers have the additional capacity for specific binding of the complex. However, PAI-1 is not detected at the surface of HepG2 cells in suspension, suggesting that 125I-t-PA.PAI-1 complexes form in substratum and subsequently bind to cells. Specific binding of performed 125I-t-PA.PAI-1, but not 125I-t-PA, was demonstrated for HepG2 cells in suspension. These results suggest that components of extracellular matrix participate in the clearance of t-PA by hepatocytes.

摘要

肝实质细胞在体内有助于清除循环中的组织型纤溶酶原激活剂(t-PA)。肝细胞膜外基质介于内皮衬里的肝血窦和实质细胞表面之间,因此可能影响t-PA的清除。为了验证这一假设,我们使用分化良好的人肝癌细胞系HepG2在体外研究细胞外基质在t-PA清除中的作用。此前对这些细胞的研究表明,在纤溶酶原激活剂抑制剂1型(PAI-1)调节的系统中,它们具有特异性分解t-PA的能力。在本研究中,HepG2细胞的细胞外基质生长底物显示含有活性PAI-1。PAI-1以点状模式分布于整个底物中。底物成分使活性PAI-1在至少24小时的时间间隔内保持稳定。将底物暴露于125I-t-PA会迅速导致形成并释放一种十二烷基硫酸钠稳定的95 kDa 125I-t-PA.PAI-1复合物。相比之下,细胞单层对该复合物具有额外的特异性结合能力。然而,在悬浮的HepG2细胞表面未检测到PAI-1,这表明125I-t-PA.PAI-1复合物在底物中形成,随后与细胞结合。悬浮的HepG2细胞对预先形成的125I-t-PA.PAI-1而非125I-t-PA表现出特异性结合。这些结果表明,细胞外基质成分参与了肝细胞对t-PA的清除。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验